Related references
Note: Only part of the references are listed.Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study
Carlo Gambacorti-Passerini et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Loss of NF-κB1 Causes Gastric Cancer with Aberrant Inflammation and Expression of Immune Checkpoint Regulators in a STAT-1-Dependent Manner
Lorraine A. O'Reilly et al.
IMMUNITY (2018)
Clinical Genomic Profiling Identifies TYK2 Mutation and Overexpression in Patients With Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors
Angela C. Hirbe et al.
CANCER (2017)
Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences
E. Waanders et al.
LEUKEMIA (2017)
Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations
Jing Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia
Koshi Akahane et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Tyrosine kinase 2-Surveillant of tumours and bona fide oncogene
Nicole R. Leitner et al.
CYTOKINE (2017)
HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia
K. Akahane et al.
LEUKEMIA (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Jeffrey C. Bryan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Next-generation sequencing identifies a novel ELAVL1-TYK2 fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208
Adriana E. Tron et al.
LEUKEMIA & LYMPHOMA (2016)
Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress
Tim I. M. Malcolm et al.
NATURE COMMUNICATIONS (2016)
Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling
Melanie R. Hassler et al.
CELL REPORTS (2016)
STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma
Chengsheng Wu et al.
BLOOD (2015)
Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma
Ramona Crescenzo et al.
CANCER CELL (2015)
Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation
Olaf Merkel et al.
JOURNAL OF PATHOLOGY (2015)
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
Vibeke Strand et al.
ARTHRITIS RESEARCH & THERAPY (2015)
A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders
Thirunavukkarasu Velusamy et al.
BLOOD (2014)
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
K. G. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance
Raimund M. Vielnascher et al.
TRANSGENIC RESEARCH (2014)
Tumor STAT1 Transcription Factor Activity Enhances Breast Tumor Growth and Immune Suppression Mediated by Myeloid-derived Suppressor Cells
Laura M. Hix et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors
Sue J. Sohn et al.
JOURNAL OF IMMUNOLOGY (2013)
TYK2-STAT1-BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia
Takaomi Sanda et al.
CANCER DISCOVERY (2013)
A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
Michelle A. Fanale et al.
CLINICAL CANCER RESEARCH (2012)
TYK2 Kinase Activity Is Required for Functional Type I Interferon Responses In Vivo
Michaela Prchal-Murphy et al.
PLOS ONE (2012)
A novel role for IL-22R1 as a driver of inflammation
Ram Savan et al.
BLOOD (2011)
Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity
Birgit Strobl et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2011)
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group
Norbert Schmitz et al.
BLOOD (2010)
Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer
N. Khodarev et al.
ONCOGENE (2010)
International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes
Julie M. Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma
J. Dien Bard et al.
LEUKEMIA (2008)
Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells
Nikolai N. Khodarev et al.
CANCER RESEARCH (2007)
Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation
Mong-Hsun Tsai et al.
CANCER RESEARCH (2007)
Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma
Yajun Han et al.
BLOOD (2006)
Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFN-γ-dependent IL-10 reactivation
Michael H. Shaw et al.
JOURNAL OF IMMUNOLOGY (2006)
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target
R Chiarle et al.
NATURE MEDICINE (2005)
Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase
SD Turner et al.
ONCOGENE (2003)
Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma
HM Amin et al.
ONCOGENE (2003)
Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells
H Ruchatz et al.
EXPERIMENTAL HEMATOLOGY (2003)
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas, and plasma cell tumors
R Chiarle et al.
BLOOD (2003)
Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line - Pathways that are shared with and distinct from IL-10
D Lejeune et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
STATs: Transcriptional control and biological impact
DE Levy et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors
GZ Rassidakis et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage
GZ Rassidakis et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Partial impairment of cytokine responses in Tyk2-deficient mice
M Karaghiosoff et al.
IMMUNITY (2000)
Share Paper
